6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 6 of 6 clinical reviews.
Evidence-based review of sildenafil safety differences in Black and African ancestry patients, covering pharmacogenomics, cardiovascular risk, G6PD, dosing, and drug interactions.
East Asian patients may need lower sildenafil starting doses due to CYP2C19 poor-metabolizer prevalence, lower average BMI, and distinct pharmacokinetic profiles. Evidence-based dosing guidance from PharmGKB, RCT subgroup data, and population PK studies.
East Asian patients metabolize sildenafil differently due to CYP2C19 poor-metabolizer rates, lower BMI thresholds, and distinct cardiovascular risk patterns. Learn how these differences affect dosing, safety, and clinical outcomes.
A clinician-reviewed guide to sildenafil dosing, pharmacogenomics, and diabetes-related ED risk in Hispanic and Latino patients, with ethnicity-stratified trial data and CYP2C9 variant guidance.
A detailed clinical review of sildenafil pharmacokinetics, pharmacogenomics, and safety considerations specific to Hispanic and Latino patients, including CYP variant data, diabetes comorbidity, and ethnicity-stratified trial subgroups.
A clinician-reviewed deep dive into how sildenafil (Viagra) performs differently in Black and African ancestry patients, covering pharmacogenomics, hypertension interactions, G6PD prevalence, CKD risk, and evidence-based dosing strategies.